1606 (72%) colon cancer survivors responded to our questionnaire. 1542 colon cancer patients treated with SU (n=1031) or SU+adjCT (n=493) were included in this study. In colon cancer patients aged <70years and aged ⩾70 no statistical significant differences on the subscales of the EORTC QLQ-C30 or the EORTC QLQ-CR38 were observed between patients treated with SU and SU+adjCT. Colon cancer patients aged <70years either treated with SU or SU+adjCT reported significantly more insomnia, diarrhoea and financial problems compared with the normative population. No differences in HRQoL were found between colon cancer patients aged ⩾70years either treated with SU or SU+adjCT and the normative population.
Patients diagnosed with colon cancer between January 2000 and June 2009, as registered within the population-based Eindhoven Cancer Registry, received a questionnaire on HRQoL (European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire version 3.0 (QLQ-C30)) and disease-specific symptoms (EORTC QLQ-Colorectal 38 (EORTC QLQ-CR38)) in 2010. The first was also completed by the normative population (n=685).
No differences in HRQoL and disease-specific symptoms were found between patients treated with SU versus SU+adjCT in both younger and elderly colon cancer patients. Withholding patients adjCT, based on concerns for long-term HRQoL or disease-specific symptoms does therefore not seem plausible.
The goal of this study was to compare health related quality of life (HRQoL) and disease-specific symptoms between colon cancer patients treated with surgery only (SU) and surgery and adjuvant chemotherapy (SU+adjCT). Results were stratified for those aged <70 and ⩾70years. HRQoL of patients was also compared with an age- and sex-matched normative population.
This website uses cookies to ensure you get the best experience on our website.